Issue Archive

The CD22-targeting monoclonal antibody inotuzumab ozogamicin was recently approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. In a Drug Advances article, Wynne and colleagues describe in detail the development and application of this novel therapeutic.

The role of microRNAs in a number of tissue differentiation processes including hematopoiesis is an area of active investigation with biological and clinical amplifications. Weiss and Ito explore the impact of microRNA-22 in megakaryocytic differentiation, demonstrating a major role for this microRNA.

Gene editing of hematopoietic stem cells with CRISPR/Cas9-gRNA holds great promise to develop new treatment options for some of the most vexing genetic disorders. However, there are many technical limitations to be overcome. Nasri and colleagues describe a novel method that is validated by editing out a gene involved in DNA repair.

The search for driver mutations is critical to the understanding of many malignancies and has yielded important targets for therapeutic intervention. To date, most of these studies have focused on coding regions of the genome. Cornish and colleagues explore the potential role of noncoding regions of the genome in a large cohort of lymphoma patients.

Patients with myelofibrosis present a challenging clinical dilemma. The only curative therapy is allogeneic hematopoietic cell transplantation. Still, because of the variability in clinical course, comorbid medical conditions, and disease status, the decision to proceed is often difficult. Snyder and colleagues analyze a large cohort of patients with myelofibrosis receiving a common preparative regimen. The cohort presents patient and disease characteristics that predict outcomes. Their findings may allow for more accurate assessments of risk and benefit.